FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.
The FDA hit pause on new patients joining a test for Biohaven's epilepsy medicine, but the main trial results will still come on time. When a regulator pumps the brakes like this, watch whether the company can solve the problem fast and keep investor trust alive.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.